Future novel single agent and combination therapies

Cancer Journal

Volumn 15, Issue 6, 2009, Pages 511-518

  Cirstea, Diana ^a   Vallet, Sonia ^a   Raje, Noopur ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone marrow microenvironment; Combination therapy; Multiple myeloma; Novel agents

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; AT 7519; BORTEZOMIB; CARFILZOMIB; CEP 18770; CNTO 328; CYCLIN DEPENDENT KINASE INHIBITOR; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; EVEROLIMUS; FTI 5777; GRN 163L; LENALIDOMIDE; MELPHALAN; NSC 639966; P 276 00; PANOBINOSTAT; PERIFOSINE; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; RGB 286638; ROMIDEPSIN; ROSCOVITINE; SALINOSPORAMIDE A; SORAFENIB; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; LOW DRUG DOSE; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE PROGRESSION; HUMANS; MELPHALAN; MULTIPLE MYELOMA; OLIGOPEPTIDES; PREDNISOLONE; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; PYRAZINES;

EID: 75149186208     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181c51c8e     Document Type: Review

References (97)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521-2526.
3. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, doubleblind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171-2177.
4. San Miguel JF, Schlag R, Khuageva NK, et al; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.
5. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
6. Richardson PG, Sonneveld P, Schuster MW, et al; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
7. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. In press.
8. Weber DM, Chen C, Niesvizky R, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133-2142.
9. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol. 2009;146:164-170.
10. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892-3901.
11. Dimopoulos M, Spencer A, Attal M, et al; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-2132.
12. Rajkumar SV, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. Annual Meeting Abstracts 2007;25(suppl 18):LBA8025.
13. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2007;110: 31a. [Abstract 74].
14. Jagannath S, Vij R, Stewart AK, et al. Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). Blood. 2008;112:Abstract 864.
15. Jagannath S, Vij R, Stewart AK, et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2009;27(suppl 15):Abstract 8504.
16. Vij R, Wang M, Orlowski R, et al. Initial results of PX-171-04, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). Blood. 2008;112:Abstract 865.
17. Niesvizky R, Bensinger W, Vallone M, et al. PX-171-006: phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): preliminary results. J Clin Oncol. 2009;27:15s (suppl; Abstract 8541).
18. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005;8:407-419. (Pubitemid 41579835)
19. Piva R, Ruggeri B, Williams M, et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood. 2008;111:2765-2775.
20. Hofmeister CC, Richardson P, Zimmerman T, et al. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/ refractory multiple myeloma (r/r MM). J Clin Oncol. 2009;27:15s (suppl; Abstract 8505).
21. Chauhan D, Singh A, Brahmandam M, et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008;111:1654-1664.
22. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
23. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
24. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
25. Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004;79:875-882.
26. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322.
27. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-4530.
28. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950-1961.
29. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone (pom/dex) is highly effective therapy in relapsed multiple myeloma. Blood. 2008;112:Abstract 866.
30. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004;101:540-545.
31. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102:2615-2622.
32. O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166-173.
33. Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49:502-507.
34. Wolf JL, Siegel D, Matous J, et al. A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma. Blood. 2008;112:Abstract 2774.
35. Ottmann OG, Spencer A, Prince HM, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. Blood. 2008;112:Abstract 958.
36. Deleu S, Lemaire M, Arts J, et al. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res. 2009;69: 5307-5311.
37. Badros AZ, Philip S, Niesvizk R, et al. Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts). J Clin Oncol. 2008;26:Abstract 8548.
38. Harrison S, Quach H, Yuen K, et al. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. Blood. 2008;112:Abstract 3698.
39. Siegel D, Weber D, Mitsiades CS, et al. A phase I study of vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2008;112:Abstract 3705.
40. Weber D, Jagannath S, Mazumder A, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma. Blood. 2007;110:Abstract 1172.
41. Siegel DS, Weber DM, Mitsiades CS, et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a phase I study. J Clin Oncol. 2009;27:15s (suppl; Abstract 8586).
42. Spencer A, Taylor K, Lonial S, et al. Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). J Clin Oncol. 2009;27:15s (suppl; Abstract 8542).
43. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 2002;99:14374-14379.
44. Chanan-Khan A, Richardson P, Alsina M, et al. Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM). J Clin Oncol. 2006;24:18S (suppl; Abstract 3066).
45. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007;138:783-791.
46. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3+-kinase/AKT signaling. Cancer Res. 2003;63:5850-5858.
47. Hsu J, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001;98:2853-2855.
48. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053-4062.
49. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood. 2007;109:711-719.
50. Richardson P, Wolf J, Jakubowiak A, et al. Phase I/II results of a multicenter trial of perifosine (KRX-0401) - bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. Blood. 2008;112:Abstract 870.
51. Jakubowiak A, Richardson P, Zimmerman TM, et al. Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). Blood. 2008;112:Abstract 3691.
52. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007;109:1669-1677.
53. Hideshima T, Chauhan D, Richardson P, et al. Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol. 2005;23:6345-6350.
54. Hideshima T, Raje N. Akt as a therapeutic target in multiple myeloma. Haematologica. 2007;92[suppl 2]:abstract n. S8.3.
55. Anderson KC. Future perspectives in the management of myeloma. Haematologica. 2007;92[suppl. 2]:abstract n.S13.4.
56. Shi Y, Hsu JH, Hu L, et al. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6. J Biol Chem. 2002;277:15712-15720.
57. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002;62:5027-5034.
58. Hu L, Shi Y, Hsu JH, et al. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003;101:3126-3135.
59. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004;104:4188-4193.
60. Strömberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004;103:3138-3147.
61. Yan H, Frost P, Shi Y, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasoneinduced apoptosis. Cancer Res. 2006;66:2305-2313.
62. Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood. 2004;104:4181-4187.
63. Mitsiades N, McMullan C, Poulaki V, et al. The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo. ASH Annual Meeting Abstracts. 2004;104:1496.
64. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006;25: 6436-6446.
65. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671-688.
66. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9-22.
67. Farag SS, Zhang S, Jansak BS, et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res. 2009;33:1475-1480.
68. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007; 26:1932-1940.
69. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005;65:7052-7058.
70. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66: 1500-1508.
71. Cirstea D, Hideshima T, Pozzi S, et al. Combination of Nab-rapamycin and perifosine induces synergistic cytotoxicity and antitumor activity via autophagy and apoptosis in multiple myeloma (MM). Blood. 2008;112:Abstract 3663.
72. Ghobrial IM, Munshi N, Schlossman R, et al. Phase I trial of CCI-779 (temsirolimus) and weekly bortezomib in relapsed and/or refractory multiple myeloma. Blood. 2008;112:Abstract 3696.
73. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333-6338.
74. Baughn LB, Di Liberto M, Wu K, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66:7661-7667.
75. Raje N, Kumar S, Hideshima T, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005;106:1042-1047.
76. Raje N, Hideshima T, Mukherjee S, et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia. 2009;23:961-970.
77. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29:3945-3950.
78. Puthier D, Derenne S, Barillé S, et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol. 1999;107:392-395.
79. Cirstea D, Hideshima T, Pozzi S, et al. RGB 286638, a novel multi-targeted small molecule inhibitor, induces multiple myeloma (MM) cell death through abrogation of CDK-dependent and independent survival mechanisms. Blood. 2008:112:Abstract 2759.
80. Santo L, Vallet S, Hideshima T, et al. ASH 2008-AT7519, a novel small molecule multi-cyclin dependent kinase inhibitor, induces apoptosis in multiple myeloma VIA GSK3+. Blood. 2008;112:Abstract 251.
81. Kurihara N, Bertolini D, Suda T, et al. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol. 1990;144:4226-4230.
82. Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res. 2007;13:6469-6478.
83. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329-1337.
84. Neri P, Kumar S, Fulciniti MT, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007;13:5903-5909.
85. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66:6675-6682.
86. Shammas MA, Koley H, Bertheau RC, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 2008;22:1410-1418.
87. Chanan-Khan AA, Munshi NC, Hussein MA, et al. Results of a phase I study of GRN163L, a direct inhibitor of telomerase, in patients with relapsed and refractory multiple myeloma (MM). Blood. 2008;112:Abstract 3701.
88. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001;18:212-224.
89. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004;103:3271-3277.
90. Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res. 2006;12:591-599.
91. Lonial S, Francis D, Karanes C, et al. A phase i mmrc clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma. Blood. 2008;112:Abstract 3706.
92. Srkalovic G, Hussein M, Bolejack V, et al. A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434). J Clin Oncol. 2009;27(suppl):Abstract e19517.
93. Orlowski RZ, Stewart K, Vallone M, et al. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results. Blood (ASH Annual Meeting Abstracts). 2007;110:409.
94. Alsina M, Trudel S, Vallone M, et al. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood (ASH Annual Meeting Abstracts). 2007;110:411.
95. Richardson P, Chanan-Khan AA, Lonial S, et al. A multicenter phase 1 clinical trial of tanespimycin (KOS-953) - bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts). 2006;108:406.
96. Weber D, Badros AZ, Jagannath S, et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. Blood. 2008;112:Abstract 871.
97. Siegel D, Sezer O, San Miguel JF, et al. A phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. Blood. 2008;112:Abstract 2781.